Drug Trial Radar · NCT07511127
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Feb 28, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Conditions
- Hematologic Malignancy
Interventions
MaribavirDrug
During the treatment period, maribavir is administered orally at a dosage of 400 mg twice daily. Participants will be stratified by clinical trial and received oral medication for varying durations.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of recurrent CMV infectionTime frame: The primary endpoint is assessed 8 weeks after maribavir discontinuation following allo-HSCT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.